Glenmark launches Remogliflozin combo in India; GeneCentric Therapeutics buys Select ImmunoGenomics
→ India’s Glenmark in April launched domestically a new SGLT2 inhibitor called Remogliflozin — marking the first-ever launch of the diabetes drug, which was partly developed by GSK $GSK. SGLT2 inhibitors, such as Forxiga, Invokana and Jardiance, work by preventing the kidneys from reabsorbing glucose back into the blood. Remogliflozin will now also be sold in combination with the decades-old metformin in India, Glenmark said on Monday.
→ GeneCentric Therapeutics, whose technology is engineered to isolate genetic signatures that could help identify appropriate populations that will respond to oncology treatments, has acquired Select ImmunoGenomics, which assists immuno-oncology drug makers by providing advanced immunogenomic, data analysis and biomarker development services. The combined entity is positioning itself as a one-stop-shop for immunotherapy development “by identifying the right patients for oncology drugs, improving response rates and durability, and ultimately patient outcomes.” No financial details were disclosed.
→ Having lifted its shares out of penny-stock territory, Generex $GNBT says it’s locked in an unnamed vehicle that its NuGenerex spinout can ride on to a Nasdaq listing $NGIO. The immuno-oncology focused subsidiary, previously known as Antigen Express, has scored a collaboration with Merck, combining its peptide vaccine with Keytruda. Once it becomes a public company, NuGenerex will also merge with Kiromic, which brings several platform techs spanning CAR-T, CAR-NK and oral vaccine delivery as well as a partnership with MD Anderson.